Department of Obstetrics and Gynaecology

Quadrivalvular nonbacterial thrombotic endocarditis in a patient with clear cell cervical cancer (2022) Gabelmann V, Grabs F, Diestelmeier S, Heindl F, Vosseler M, Muenzel T, Sagoschen I, Wild J Journal article Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial (2022) González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, et al. Journal article AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022 (2022) Banys-Paluchowski M, Thill M, Kuhn T, Ditsch N, Heil J, Woeckel A, Fallenberg E, et al. Journal article Advanced Breast Cancer: AGO Recommendations 2022 Focus on ABC6 Consensus Fortgeschrittenes Mammakarzinom ABC6-Konsens im Fokus der AGO-Empfehlungen 2022 (2022) Untch M, Fasching P, Haidinger R, Harbeck N, Jackisch C, Lüftner D, Müller V, et al. Journal article, Review article Individual dynamics of uterine natural killer cells in natural and stimulated cycles monitored using a new endometrial dating method (2022) Alfer J, Fattahi A, Bleisinger N, Antoniadis S, Krieg J, Dittrich R, Beckmann M, et al. Journal article A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression (2022) Tzaridis T, Weller J, Bachurski D, Shakeri F, Schaub C, Hau P, Buness A, et al. Journal article HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 (2022) Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, et al. Conference contribution Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies (2022) Haegele M, Mueller KR, Denkert C, Schneeweiss A, Sinn BV, Untch M, Van Mackelenbergh MT, et al. Conference contribution When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study (2022) Hampl M, Jaeger A, Eulenburg C, Prieske K, Hambrecht J, Fuerst S, Klapdor R, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis (2022) Cortes J, Haiderali A, Huang M, Pan W, Fox GE, Park J, Frederickson AM, et al. Conference contribution